Woodline Partners LP Has $18.04 Million Stake in CG Oncology, Inc. (NASDAQ:CGON)

Woodline Partners LP lifted its position in CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 3.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 628,885 shares of the company's stock after buying an additional 22,987 shares during the quarter. Woodline Partners LP owned about 0.83% of CG Oncology worth $18,036,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of CG Oncology in the 4th quarter valued at approximately $68,000. KLP Kapitalforvaltning AS bought a new stake in shares of CG Oncology in the 4th quarter valued at approximately $100,000. Federated Hermes Inc. acquired a new stake in CG Oncology in the 4th quarter worth approximately $172,000. Meeder Asset Management Inc. acquired a new stake in CG Oncology in the 4th quarter worth approximately $189,000. Finally, NEOS Investment Management LLC lifted its holdings in CG Oncology by 10.9% in the 4th quarter. NEOS Investment Management LLC now owns 8,329 shares of the company's stock worth $239,000 after purchasing an additional 817 shares during the last quarter. Institutional investors own 26.56% of the company's stock.

CG Oncology Stock Down 1.7%

Shares of CGON stock traded down $0.43 during trading hours on Tuesday, reaching $25.02. 88,014 shares of the company's stock were exchanged, compared to its average volume of 1,064,314. CG Oncology, Inc. has a fifty-two week low of $14.80 and a fifty-two week high of $40.47. The stock has a market capitalization of $1.91 billion, a P/E ratio of -16.63 and a beta of 1.08. The business has a fifty day moving average price of $23.21 and a 200-day moving average price of $27.56.

CG Oncology (NASDAQ:CGON - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.45) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.09). CG Oncology had a negative return on equity of 18.97% and a negative net margin of 10,642.98%. The business had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.53 million. As a group, research analysts expect that CG Oncology, Inc. will post -1.31 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Royal Bank of Canada boosted their target price on CG Oncology from $66.00 to $68.00 and gave the stock an "outperform" rating in a report on Tuesday, April 29th. HC Wainwright restated a "buy" rating and issued a $75.00 target price on shares of CG Oncology in a report on Monday, April 28th. Morgan Stanley reduced their target price on CG Oncology from $55.00 to $52.00 and set an "overweight" rating for the company in a report on Monday, May 19th. JPMorgan Chase & Co. assumed coverage on CG Oncology in a report on Friday, May 2nd. They issued an "overweight" rating and a $41.00 target price for the company. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $75.00 target price on shares of CG Oncology in a report on Monday, April 28th. One research analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, CG Oncology presently has an average rating of "Buy" and an average target price of $58.22.

Insider Transactions at CG Oncology

In other news, Director Leonard E. Post sold 1,000 shares of the company's stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $30.76, for a total transaction of $30,760.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 7.40% of the company's stock.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.